a syringe in complete medium (CM) . The cell suspension was passed through 100-gauge nylon mesh (Nitex ; Lawshe Instrument Co., Rockville, MD), and the erythrocytes were lysed by hypotonic shock with buffered ammonium chloride solution at room temperature for 2 min . The cells were then centrifuged and washed twice in CM .
CM consisted of RPMI 1640 (Biofluids) with 10% heat-inactivated FCS (Biofluids), 0 .03% fresh glutamine (NIH Media Unit), 0 .1 mM nonessential amino acids (M. A .
Bioproducts, Walkersville, MD), 5 X 10 -5 M 2-ME (Aldrich Chemical Co ., Inc ., Milwaukee, WI), 100 Ag/ml penicillin (NIH Media Unit), 100 Eg/ml streptomycin (NIH Media Unit), 50 wg/ml gentamicin (Schering, Kenilworth, NJ), and 0 .5 Ag/ml Fungizone (Flow Laboratories, McLean, VA) .
Lymphokines. Human rIL-2 was kindly supplied by the Cetus Corp ., Emeryville, CA .
The biological and biochemical activities of rIL-2 have been described (2) . Purified material had a specific activity of 8 X 106 U/mg as measured in a standard bioassay using T cell line 53 (2, 3) . The endotoxin level in the purified preparation was <0.1 mg per 10 6 U rIL-2 as measured by a standard limulus assay.
Native interleukin 4 (nIL-4) was purified to homogeneity from the supernatant of the Con A-induced CI .Ly-1', -2 -/9 T cell line (7) . rIL-4 was purified to homogeneity from the supernatant of COS-7 monkey cells transfected with a full-length cDNA clone encoding murine IL-4 (8) . The specific activity of both forms was 7 X 10 7 U/mg in a ['Hlthymidine HT-2 T cell proliferation assay (7, 8) .
Generation of LAK Cells . 1 ml of CM containing 4 X 106 viable C57BL/6 splenocytes was added to each well of a 24-well Costar tissue culture plate (3524 ; Costar, Cambridge, MA). 1 ml of CM containing varying amounts of lymphokine was also added to each well . The cultures were incubated for 4-7 d at 37°C with 5% C02 . Cytotoxicity Assay. A standard 4-h 5 'Cr-release assay was used to measure cytotoxicity against tumor cells as described previously (11) .
Antibody and Complement Lysis of Splenocytes. Normal splenocytes were adjusted to a concentration of 2 X 107 cells/ml of cytotoxicity medium containing a 1 :50 dilution of rabbit anti-asialo-GM, serum (Wako Chemicals, Dallas, TX) . Cytotoxicity medium consisted of RPMI 1640 with 0 .3% BSA and 0 .1 mM Hepes buffer . After incubation with intermittent agitation for 60 min at 4°C, cells were centrifuged and were resuspended in a half-equal volume of cytotoxicity medium with rabbit complement (Low-Tox-M ; Accurate Chemical and Scientific Corp ., Westbury, NY) at 1 :8 dilution. Incubation was continued for an additional 60 min at 37°C with intermittent shaking. The complement treatment was repeated once again and the cells were then washed twice and were resuspended in CM .
Results and Discussion
Various concentrations of murine nIL-4, murine rIL-4, human rIL-2, or the combination of IL-4 plus IL-2 were added to C57BL/6 splenocytes and incubated for 4 d . These cells were then tested in a 4-h "Cr-release assay for the capacity to lyse the fresh, syngeneic, NK-resistant sarcoma target, MCA-102 . Table I shows that 500 U of nIL-4 or 1,000 U of rIL-4/ml generated 141 ± 4 and 461 Native Recombinant C57BL/6 mouse splenocytes were cultured at 2 X 10 6 cells/ml in 2 ml of complete medium containing varying amounts of Isymphokine. After 4 d the cells were tested for cytolytic activity against 'Cr-labeled, fresh MCA-induced sarcoma cells (MCA-102) in a 4-h assay. * 1 LU is defined as the number of effector cells mediating 30% specific lysis of 10' target cells, and is determined from the dose-response curve. LU presented as mean ± SEM of triplicate wells.
against three distinct MCA-sarcoma targets (102, 105, 106) is shown in Table  11 . Interexperiment variability in the generation of LAK activity by IL-2 or IL-4 is evident, since in most experiments suboptimal concentrations of lymphokines were tested, and we used freshly-resected tumor cells rather than cultured lines as targets. The recoveries of splenocytes from 4-or 5-d cultures (as a percentage of the initial number of cells plated) varied slightly between experiments, and were -50% for IL-2 and 30% for IL-4; those for IL-4 plus IL-2 were equivalent to IL-2 alone. We reported previously that the murine precursor cell that gives rise to LAK cells after HL-2 stimulation expresses surface asialo-GM, (11). Thus we analyzed whether or not the precursor activated by IL-4 similarly expressed surface asialo-GM, by pretreating normal C57BL/6 splenocytes with specific heteroantiserum plus complement before lymphokine activation. Fig. 1 shows that depletion of asialo-GM,-positive cells resulted in a near complete elimination of both the IL- 4 and the rIL-2-induced LAK activity . Furthermore, preliminary experiments (Mule, Smith, and Rosenberg, unpublished results) indicate that specific depletion of mature T cells has little detectable effect on LAK generation by IL-4. IL-4 generated killer cells do not appear to lyse normal cells . For example, in an experiment in which IL-4-generated killer cells showed 137 LU of activity against the MCA-102 sarcoma target, <1 LU of activity was noted against syngeneic fresh peripheral blood lymphocytes, bone marrow, kidney, lung, and LPSstimulated splenic blasts . Taken together, these results demonstrate that the lymphokine IL-4 is capable of inducing cells with LAK activity that lyse fresh tumor cell targets in vitro from an asialo-GM,-positive precursor. IL-4 and IL-2 precursor-effector relationships, as well as the effector phenotype of IL-4-activated killer cells, however, remain to be determined . Preliminary experiments (Mule et al ., unpublished results) indicate that, unlike IL-2, IL-4 has little if any capacity to generate LAK activity from mouse peripheral blood lymphocytes, whereas both lymphokines induce this activity from splenocytes. Whether or not purified human IL-4 similarly generates LAK activity from human lymphocytes remains to be'determined. (14) and IgE (15) production by mitogen-activated B cells, (d) a mast cell growth factor activity that synergizes with IL-3, and a T cell growth factor activity (7, 8) . The results reported here expand the IL-4 activities to include the induction of LAK activity from normal resting splenocytes as well as the augmentation of this activity in combination with IL-2 .
Summary
Interleukin 4 (IL-4) expresses multiple biologic activities, including B cell, mast cell, and T cell stimulation . We showed that the incubation of resting splenocytes from C57BL/6 mice solely in purified native or recombinant mouse IL-4 results in the generation of lymphokine-activated killer (LAK) activity directed against fresh, syngeneic sarcoma cells. The precursor activated by IL-4 expresses surface asialo-GM I . In addition, IL-4 is capable of amplifying the splenic LAK activity induced by recombinant IL-2 . The generation, by IL-4, of killer cells with broad antitumor reactivity raises the possibility of using IL-4 alone or in combination with IL-2 in the immunotherapy of cancer in animal models . References 1 . Grimm, E. A'., and S. A. Rosenberg. 1983 . Th e human lymphokine-activated killer cell phenomenon . Lymphokines . 9:279 . 
